Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management
Launched by DR. ASMA ABDUS SALAM · May 21, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how genetic differences among patients might affect the effectiveness of a pain medication called Nalbuphine after surgery. The researchers want to understand if certain genes can predict how well Nalbuphine works for managing pain following various types of abdominal surgeries, such as gallbladder removal, hernia repair, and hysterectomy. The goal is to learn more about pain management in order to improve patient care and help address issues related to opioid use.
To participate in the study, you need to be an adult between 18 and 70 years old who is scheduled for a surgery lasting 2 to 4 hours. You will first provide a small blood sample before your surgery, and then receive Nalbuphine as part of your anesthesia. After surgery, another blood sample will be taken, and your pain levels and any side effects will be monitored for 24 hours. It's important to know that this study is not recruiting participants yet, and some individuals, like those with certain medical conditions or taking specific medications, may not be eligible to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All adult men or women
- • 2. Age 18 to 70 years
- • 3. ASA criteria 1,2 and 3
- • 4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours
- Exclusion Criteria:
- • 1. Surgical procedure duration lasting more than 4 hours
- • 2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,
- • 3. History of hypersensitivity or allergy to opioids,
- • 4. Pregnant or breastfeeding mothers,
- • 5. History of narcotic dependency, addiction, and withdrawal
- • 6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission
- • 7. Refusing to participate in the study
- • 8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks
About Dr. Asma Abdus Salam
Dr. Asma Abdus Salam is a dedicated clinical trial sponsor renowned for her commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and extensive experience in managing complex trials, she leads initiatives that prioritize safety, efficacy, and ethical standards. Dr. Abdus Salam collaborates with multidisciplinary teams to design and implement innovative study protocols, ensuring compliance with regulatory guidelines while fostering an environment of scientific integrity. Her passion for translating research findings into tangible healthcare solutions positions her as a respected leader in the clinical trial landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Talat Mirza, FCPS PhD
Study Director
Ziauddin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported